Doctor-patient differences

For the first time, an international survey identifies the main treatment issues. The results for the United States are without appeal: the undesirable effects of treatments combined with a lack of communication between patients and doctors limit the effectiveness of the treatment.

Children and asthma: uninformed parents

The Global Asthma Physician and Patient (GAPP) survey was conducted in 16 countries to investigate attitudes and therapeutic practices towards asthma. Asthma, both from the point of view of doctors and patients. Three main areas were examined in this study: adverse drug reactions, treatment adherence and patient education.

The results of the GAPP survey for the United States are unequivocal and highlight two main obstacles to effective management: the lack of communication between physicians and their patients and the occurrence of adverse effects related to treatment with Inhaled corticosteroids.

The results of the Gapp survey provide a unique insight into the current state of asthma treatment in the United States, both from the point of view of doctors and adult patients. In addition to caring for adults, the Gapp survey has also focused on the treatment of children with asthma. The results confirm the need to improve both the tolerance of the proposed treatments and the information of the parents.

An asthma attack can be fatal even in children with moderate asthma, a reality ignored by 49% of parents of asthmatic children. This result demonstrates the lack of communication between doctors and parents of children with asthma. A fact confirmed by this other result: the majority of parents of children who received asthma treatment claimed to have rarely or never reported short-term (58%) and long-term (67%) adverse effects with Physician of their child. However, 86% of doctors say they sometimes or always talk about side effects in the short term, and 65% say they sometimes or always talk about long-term adverse events.

Adverse reactions that affect adherence to treatment in both children and adults. Finally, 80% of the parents surveyed believe that new treatments are needed.

Recall that asthma affects 300 million people worldwide and causes 180,000 deaths annually. In the United States, nearly 7% of the population suffers from this disease.

* In order to better understand the barriers to optimal treatment of asthma in adult patients, Harris Interactive conducted 3,459 interviews (online, telephone or direct) with 1,726 adults on behalf of the GAPP survey Aged at least 18 years and diagnosed with asthma, and 1,733 physicians (general practitioners and specialists) treating adult patients. The interviews carried out in the United States concerned 102 adult asthmatic patients and 100 doctors (50 general practitioners and 50 specialists) treating adult patients. The GAPP survey received a donation from ALTANA Pharma

Press release Altana Pharma

ALL ASTHMA TREATMENTS

INHALER ANTICHOLINERGICS

Stimulating beta2 bronchodilators

Antileukotrienes

Antihistamines

The corticosteroids

Monoclonal antibodies




Patients and physicians: misunderstandings persist Patients and doctors have divergent views on adverse reaction information More than half of the patients who received treatment reported that they had never spoken about adverse events in the short term ( 63%) and long (60%) with their physicians, but 87% of physicians say they sometimes or always talk about side effects in the short term, and 32% The perception of patient training in the practice varies considerably between patients and physicians, with 62% of physicians reporting more than a quarter of the consultation time on techniques to ensure treatment success, Only 23% of patients 26% of physicians report that they have a daily diary of symptoms for their patients, while only 7% of patients report having such a conversation with their physician. Of adverse events influence adherence, 21% of patients with anti-asthmatic treatment reported short-term adverse events and 11% of long-term adverse events. Undesirable effects are 50% to report that they have considered reducing dosage, and 29% have reduced it.